Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > New Corp Presentation is up

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Aug 10, 2022 11:16am

140 Views

Post# 34884859

RE:RE:New Corp Presentation is up

They gave us a little new info too. I am not sure why they are not highlighting the fact that the one patient had failed on straight docetaxel but had 53% tumor shrinkage after just three treatments on TH-1902. It is really too bad that patient caught covid and had to discontinue.

qwerty22 wrote:
Much clearer.

SPCEO1 wrote:

And it has a little new info on cancer - nothing on phase 1b but some more info on phase 1a regarding side-effects and number of patients treated at different dosage levels.